NCT01507194View on ClinicalTrials.gov

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG

Ondansetron

Single IV dose

DRUG

Vestipitant

Single IV dose

Trial Locations (7)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

15232

University of Pittsburg, Pittsburgh

27157

Wake Forest University Anesthesia at Forsyth Medical Center, Winston-Salem

33472

Visions Clinical Research, Boynton Beach

35660

Helen Keller Hospital, Sheffield

85032

Precision Trials, Phoenix

02135

CAP Anesthesia (St. Elizabeth's Medical Center), Boston

Sponsors

Lead Sponsor

Accenture
All Listed Sponsors
lead

Accenture

INDUSTRY

NCT01507194 - A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) | Biotech Hunter | Biotech Hunter